{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T22:26:13Z","timestamp":1794263173580,"version":"4.9.0"},"reference-count":106,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003792","name":"Hj\u00e4rnfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008599","name":"Alzheimerfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008599","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["2024\\u201302963"],"award-info":[{"award-number":["2024\\u201302963"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["2021\\u201303524"],"award-info":[{"award-number":["2021\\u201303524"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.tjpad.2025.100214","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T15:18:43Z","timestamp":1748272723000},"page":"100214","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Bispecific brain-penetrant antibodies for treatment of Alzheimer\u2019s disease"],"prefix":"10.1016","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9430-3859","authenticated-orcid":false,"given":"Dag","family":"Sehlin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4136-6792","authenticated-orcid":false,"given":"Greta","family":"Hultqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3096-3604","authenticated-orcid":false,"given":"Wojciech","family":"Michno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7601-8862","authenticated-orcid":false,"given":"Ximena","family":"Aguilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5765-1002","authenticated-orcid":false,"given":"Amelia D","family":"Dahl\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5154-5180","authenticated-orcid":false,"given":"Enrica","family":"Cerilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2832-0732","authenticated-orcid":false,"given":"Nadja M","family":"Bucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3874-6962","authenticated-orcid":false,"given":"Sara","family":"Lopes van den Broek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8196-4041","authenticated-orcid":false,"given":"Stina","family":"Syv\u00e4nen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tjpad.2025.100214_bib0001","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.biopsych.2017.08.010","article-title":"Anti-amyloid-beta monoclonal antibodies for Alzheimer's disease: pitfalls and promise","volume":"83","author":"van Dyck","year":"2018","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.tjpad.2025.100214_bib0002","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jalz.2015.12.003","article-title":"Why has therapy development for dementia failed in the last two decades?","volume":"12","author":"Gauthier","year":"2016","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2025.100214_bib0003","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa1304839","article-title":"Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease","volume":"370","author":"Salloway","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tjpad.2025.100214_bib0004","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S1474-4422(10)70043-0","article-title":"11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study","volume":"9","author":"Rinne","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.tjpad.2025.100214_bib0005","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-75204-8","article-title":"Critical assessment of anti-amyloid-beta monoclonal antibodies effects in Alzheimer's disease: a systematic review and meta-analysis highlighting target engagement and clinical meaningfulness","volume":"14","author":"Avgerinos","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.tjpad.2025.100214_bib0006","doi-asserted-by":"crossref","first-page":"771","DOI":"10.14283\/jpad.2023.123","article-title":"Lecanemab clarity AD: quality-of-life results from a randomized, double-blind phase 3 trial in early Alzheimer's disease","volume":"10","author":"Cohen","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.tjpad.2025.100214_bib0007","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer's disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tjpad.2025.100214_bib0008","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1001\/jamaneurol.2021.4161","article-title":"Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early Alzheimer disease","volume":"79","author":"Salloway","year":"2022","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.tjpad.2025.100214_bib0009","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early Alzheimer's disease","volume":"384","author":"Mintun","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tjpad.2025.100214_bib0010","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.tjpad.2025.100214_bib0011","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1056\/NEJMoa2304430","article-title":"Two phase 3 trials of gantenerumab in early Alzheimer's disease","volume":"389","author":"Bateman","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tjpad.2025.100214_bib0012","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-61691-2","article-title":"Amyloid-beta antibody binding to cerebral amyloid angiopathy fibrils and risk for amyloid-related imaging abnormalities","volume":"14","author":"Soderberg","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.tjpad.2025.100214_bib0013","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12987-023-00435-2","article-title":"Age, dose, and binding to TfR on blood cells influence brain delivery of a TfR-transported antibody","volume":"20","author":"Faresjo","year":"2023","journal-title":"Fluids Barriers CNS"},{"key":"10.1016\/j.tjpad.2025.100214_bib0014","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.neuron.2015.09.036","article-title":"Lack of widespread BBB disruption in Alzheimer's disease models: focus on therapeutic antibodies","volume":"88","author":"Bien-Ly","year":"2015","journal-title":"Neuron"},{"key":"10.1016\/j.tjpad.2025.100214_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuropharm.2018.09.001","article-title":"Blood-brain barrier integrity in a mouse model of Alzheimer's disease with or without acute 3D6 immunotherapy","volume":"143","author":"Gustafsson","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.tjpad.2025.100214_bib0016","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1113\/JP275105","article-title":"Intrathecal antibody distribution in the rat brain: surface diffusion, perivascular transport and osmotic enhancement of delivery","volume":"596","author":"Pizzo","year":"2018","journal-title":"J Physiol"},{"key":"10.1016\/j.tjpad.2025.100214_bib0017","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1038\/s41467-025-57108-x","article-title":"Fc-engineered large molecules targeting blood-brain barrier transferrin receptor and CD98hc have distinct central nervous system and peripheral biodistribution","volume":"16","author":"Khoury","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.tjpad.2025.100214_bib0018","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0079-6123(08)62329-8","article-title":"Localization patterns for immunoglobulins and albumins in the brain suggest diverse mechanisms for their transport across the blood-brain barrier (BBB)","volume":"91","author":"Kozlowski","year":"1992","journal-title":"Prog Brain Res"},{"key":"10.1016\/j.tjpad.2025.100214_bib0019","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s40035-020-00214-1","article-title":"SPECT imaging of distribution and retention of a brain-penetrating bispecific amyloid-beta antibody in a mouse model of Alzheimer's disease","volume":"9","author":"Gustavsson","year":"2020","journal-title":"Transl Neurodegen"},{"key":"10.1016\/j.tjpad.2025.100214_bib0020","doi-asserted-by":"crossref","first-page":"84ra44","DOI":"10.1126\/scitranslmed.3002230","article-title":"Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target","volume":"3","author":"Yu","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.tjpad.2025.100214_bib0021","doi-asserted-by":"crossref","first-page":"84ra43","DOI":"10.1126\/scitranslmed.3002254","article-title":"A therapeutic antibody targeting BACE1 inhibits amyloid-beta production in vivo","volume":"3","author":"Atwal","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.tjpad.2025.100214_bib0022","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1084\/jem.20131660","article-title":"Transferrin receptor (TfR) trafficking determines brain uptake of TfR antibody affinity variants","volume":"211","author":"Bien-Ly","year":"2014","journal-title":"J Exp Med"},{"key":"10.1016\/j.tjpad.2025.100214_bib0023","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.neuron.2013.10.061","article-title":"Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle","volume":"81","author":"Niewoehner","year":"2014","journal-title":"Neuron"},{"key":"10.1016\/j.tjpad.2025.100214_bib0024","first-page":"219","article-title":"Molecular architecture determines brain delivery of a transferrin receptor-targeted lysosomal enzyme","author":"Arguello","year":"2022","journal-title":"J Exp Med"},{"key":"10.1016\/j.tjpad.2025.100214_bib0025","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/jnc.15768","article-title":"A single-chain fragment constant design enables easy production of a monovalent blood-brain barrier transporter and provides an improved brain uptake at elevated doses","volume":"165","author":"Morrison","year":"2023","journal-title":"J Neurochem"},{"key":"10.1016\/j.tjpad.2025.100214_bib0026","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12987-022-00374-4","article-title":"VHHs as tools for therapeutic protein delivery to the central nervous system","volume":"19","author":"Wouters","year":"2022","journal-title":"Fluids Barriers CNS"},{"key":"10.1016\/j.tjpad.2025.100214_bib0027","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1021\/acs.molpharmaceut.7b00937","article-title":"Enhanced delivery of galanin conjugates to the brain through bioengineering of the anti-transferrin receptor antibody OX26","volume":"15","author":"Thom","year":"2018","journal-title":"Mol Pharm"},{"key":"10.1016\/j.tjpad.2025.100214_bib0028","doi-asserted-by":"crossref","first-page":"8662","DOI":"10.1073\/pnas.1307152110","article-title":"Transcytosis and brain uptake of transferrin-containing nanoparticles by tuning avidity to transferrin receptor","volume":"110","author":"Wiley","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.tjpad.2025.100214_bib0029","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2021.1874121","article-title":"Brain pharmacokinetics of anti-transferrin receptor antibody affinity variants in rats determined using microdialysis","volume":"13","author":"Chang","year":"2021","journal-title":"MAbs"},{"key":"10.1016\/j.tjpad.2025.100214_bib0030","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12987-023-00462-z","article-title":"Enhanced in vivo blood brain barrier transcytosis of macromolecular cargo using an engineered pH-sensitive mouse transferrin receptor binding nanobody","volume":"20","author":"Esparza","year":"2023","journal-title":"Fluids Barriers CNS"},{"key":"10.1016\/j.tjpad.2025.100214_bib0031","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0145820","article-title":"Engineering an anti-transferrin receptor ScFv for pH-sensitive binding leads to increased intracellular accumulation","volume":"10","author":"Tillotson","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.tjpad.2025.100214_bib0032","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0096340","article-title":"A human blood-brain barrier transcytosis assay reveals antibody transcytosis influenced by pH-dependent receptor binding","volume":"9","author":"Sade","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.tjpad.2025.100214_bib0033","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s004180050266","article-title":"Immunohistochemical localization of the murine transferrin receptor (TfR) on blood-tissue barriers using a novel anti-TfR monoclonal antibody","volume":"110","author":"Kissel","year":"1998","journal-title":"Histochem Cell Biol"},{"key":"10.1016\/j.tjpad.2025.100214_bib0034","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1021\/mp900235k","article-title":"Pharmacokinetics and brain uptake of a genetically engineered bifunctional fusion antibody targeting the mouse transferrin receptor","volume":"7","author":"Boado","year":"2010","journal-title":"Mol Pharm"},{"key":"10.1016\/j.tjpad.2025.100214_bib0035","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12987-025-00643-y","article-title":"The effects of dose, valency, and affinity on TfR-mediated brain delivery in vivo","volume":"22","author":"Bonvicini","year":"2025","journal-title":"Fluids Barriers CNS"},{"key":"10.1016\/j.tjpad.2025.100214_bib0036","doi-asserted-by":"crossref","first-page":"308","DOI":"10.7150\/thno.17155","article-title":"Bivalent brain shuttle increases antibody uptake by monovalent binding to the transferrin receptor","volume":"7","author":"Hultqvist","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.tjpad.2025.100214_bib0037","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13195-018-0377-8","article-title":"Efficient clearance of Abeta protofibrils in AbetaPP-transgenic mice treated with a brain-penetrating bifunctional antibody","volume":"10","author":"Syvanen","year":"2018","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.tjpad.2025.100214_bib0038","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1007\/s13311-022-01283-y","article-title":"A brain-targeting bispecific-multivalent antibody clears soluble amyloid-beta aggregates in Alzheimer's disease mice","volume":"19","author":"Rofo","year":"2022","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.tjpad.2025.100214_bib0039","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14071412","article-title":"Reduction of alphaSYN pathology in a mouse model of PD using a brain-penetrating bispecific antibody","volume":"14","author":"Roshanbin","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.tjpad.2025.100214_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2024.e00510","article-title":"A brain-penetrant bispecific antibody lowers oligomeric alpha-synuclein and activates microglia in a mouse model of alpha-synuclein pathology","volume":"22","author":"Sehlin","year":"2025","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.tjpad.2025.100214_bib0041","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.omtm.2020.08.014","article-title":"Tetravalent bispecific tandem antibodies improve brain exposure and efficacy in an amyloid transgenic mouse model","volume":"19","author":"Do","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.tjpad.2025.100214_bib0042","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aay1359","article-title":"Brain delivery of therapeutic proteins using an Fc fragment blood-brain barrier transport vehicle in mice and monkeys","volume":"12","author":"Kariolis","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.tjpad.2025.100214_bib0043","doi-asserted-by":"crossref","unstructured":"Pizzo, Plowey, Khoury, et al. Engineering anti-amyloid antibodies with transferrin receptor targeting improves brain biodistribution and mitigates ARIA. bioRxiv. 2024:2024.07.26.604664. doi:10.1101\/2024.07.26.604664.","DOI":"10.1101\/2024.07.26.604664"},{"key":"10.1016\/j.tjpad.2025.100214_bib0044","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.medj.2022.09.007","article-title":"Enhanced delivery of antibodies across the blood-brain barrier via TEMs with inherent receptor-mediated phagocytosis","volume":"3","author":"Edavettal","year":"2022","journal-title":"Med"},{"key":"10.1016\/j.tjpad.2025.100214_bib0045","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-83627-6","article-title":"A shorter linker in the bispecific antibody RmAb158-scFv8D3 improves TfR-mediated blood-brain barrier transcytosis in vitro","volume":"14","author":"Petersen","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.tjpad.2025.100214_bib0046","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2024.2339337","article-title":"Reducing neonatal Fc receptor binding enhances clearance and brain-to-blood ratio of TfR-delivered bispecific amyloid-beta antibody","volume":"16","author":"Schlein","year":"2024","journal-title":"MAbs"},{"key":"10.1016\/j.tjpad.2025.100214_bib0047","doi-asserted-by":"crossref","first-page":"261ra154","DOI":"10.1126\/scitranslmed.3009835","article-title":"Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates","volume":"6","author":"Yu","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.tjpad.2025.100214_bib0048","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12987-021-00257-0","article-title":"Brain pharmacokinetics of two BBB penetrating bispecific antibodies of different size","volume":"18","author":"Faresjo","year":"2021","journal-title":"Fluids Barriers CNS"},{"key":"10.1016\/j.tjpad.2025.100214_bib0049","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2024.2410968","article-title":"Single domain antibody-scFv conjugate targeting amyloid beta and TfR penetrates the blood-brain barrier and interacts with amyloid beta","volume":"16","author":"Faresjo","year":"2024","journal-title":"MAbs"},{"key":"10.1016\/j.tjpad.2025.100214_bib0050","doi-asserted-by":"crossref","first-page":"13272","DOI":"10.1096\/fj.202000610RR","article-title":"Brain delivery of biologics using a cross-species reactive transferrin receptor 1 VNAR shuttle","volume":"34","author":"Sehlin","year":"2020","journal-title":"FASEB J"},{"key":"10.1016\/j.tjpad.2025.100214_bib0051","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nbt0798-677","article-title":"An efficient route to human bispecific IgG","volume":"16","author":"Merchant","year":"1998","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.tjpad.2025.100214_bib0052","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2261509","article-title":"Delivery of the Brainshuttle amyloid-beta antibody fusion trontinemab to non-human primate brain and projected efficacious dose regimens in humans","volume":"15","author":"Grimm","year":"2023","journal-title":"MAbs"},{"key":"10.1016\/j.tjpad.2025.100214_bib0053","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12987-022-00398-w","article-title":"Brain pharmacokinetics of mono- and bispecific amyloid-beta antibodies in wild-type and Alzheimer's disease mice measured by high cut-off microdialysis","volume":"19","author":"Julku","year":"2022","journal-title":"Fluids Barriers CNS"},{"key":"10.1016\/j.tjpad.2025.100214_bib0054","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1007\/s00259-023-06109-3","article-title":"Application of (89)Zr-DFO*-immuno-PET to assess improved target engagement of a bispecific anti-amyloid-ss monoclonal antibody","volume":"50","author":"Stergiou","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.tjpad.2025.100214_bib0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.3005338","article-title":"Addressing safety liabilities of TfR bispecific antibodies that cross the blood-brain barrier","volume":"5","author":"Couch","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.tjpad.2025.100214_bib0056","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12090852","article-title":"Acute and chronic dosing of a high-affinity rat\/mouse chimeric transferrin receptor antibody in mice","volume":"12","author":"Castellanos","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.tjpad.2025.100214_bib0057","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13195-023-01236-3","article-title":"Long-term effects of immunotherapy with a brain penetrating Abeta antibody in a mouse model of Alzheimer's disease","volume":"15","author":"Gustavsson","year":"2023","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.tjpad.2025.100214_bib0058","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2021.1995929","article-title":"The impact of immunogenicity on therapeutic antibody pharmacokinetics: a preclinical evaluation of the effect of immune complex formation and antibody effector function on clearance","volume":"13","author":"Opolka-Hoffmann","year":"2021","journal-title":"MAbs"},{"key":"10.1016\/j.tjpad.2025.100214_bib0059","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1080\/13543784.2023.2233892","article-title":"Clinical development of passive tau-based immunotherapeutics for treating primary and secondary tauopathies","volume":"32","author":"Panza","year":"2023","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.tjpad.2025.100214_bib0060","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40478-020-0884-2","article-title":"Pre-clinical characterisation of E2814, a high-affinity antibody targeting the microtubule-binding repeat domain of tau for passive immunotherapy in Alzheimer's disease","volume":"8","author":"Roberts","year":"2020","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.tjpad.2025.100214_bib0061","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/(SICI)1096-9861(19961125)375:4<675::AID-CNE8>3.0.CO;2-Z","article-title":"Immunohistochemical localization of intraneuronal transferrin receptor immunoreactivity in the adult mouse central nervous system","volume":"375","year":"1996","journal-title":"J Comp Neurol"},{"key":"10.1016\/j.tjpad.2025.100214_bib0062","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1474-4422(23)00247-8","article-title":"Stimulation of TREM2 with agonistic antibodies-an emerging therapeutic option for Alzheimer's disease","volume":"22","author":"Schlepckow","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.tjpad.2025.100214_bib0063","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201911227","article-title":"Enhancing protective microglial activities with a dual function TREM2 antibody to the stalk region","volume":"12","author":"Schlepckow","year":"2020","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.tjpad.2025.100214_bib0064","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1186\/s12974-020-01915-0","article-title":"Therapeutic Trem2 activation ameliorates amyloid-beta deposition and improves cognition in the 5XFAD model of amyloid deposition","volume":"17","author":"Price","year":"2020","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.tjpad.2025.100214_bib0065","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20200785","article-title":"Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer's disease model","volume":"217","author":"Wang","year":"2020","journal-title":"J Exp Med"},{"key":"10.1016\/j.tjpad.2025.100214_bib0066","doi-asserted-by":"crossref","DOI":"10.1007\/s11307-021-01591-3","article-title":"Pinpointing brain TREM2 levels in two mouse models of Alzheimer's disease","author":"Meier","year":"2021","journal-title":"Mol Imaging Biol"},{"key":"10.1016\/j.tjpad.2025.100214_bib0067","first-page":"416","article-title":"A TREM2-activating antibody with a blood-brain barrier transport vehicle enhances microglial metabolism in Alzheimer's disease models","volume":"26","author":"van Lengerich","year":"2023","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.tjpad.2025.100214_bib0068","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2022.2107971","article-title":"Discovery and engineering of an anti-TREM2 antibody to promote amyloid plaque clearance by microglia in 5XFAD mice","volume":"14","author":"Zhao","year":"2022","journal-title":"MAbs"},{"key":"10.1016\/j.tjpad.2025.100214_bib0069","doi-asserted-by":"crossref","first-page":"eabq0095","DOI":"10.1126\/scitranslmed.abq0095","article-title":"A tetravalent TREM2 agonistic antibody reduced amyloid pathology in a mouse model of Alzheimer's disease","volume":"14","author":"Zhao","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.tjpad.2025.100214_bib0070","doi-asserted-by":"crossref","first-page":"e367","DOI":"10.1212\/NXI.0000000000000367","article-title":"Safety\/tolerability of the anti-semaphorin 4D antibody VX15\/2503 in a randomized phase 1 trial","volume":"4","author":"LaGanke","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.tjpad.2025.100214_bib0071","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13024-022-00550-y","article-title":"LILRB2-mediated TREM2 signaling inhibition suppresses microglia functions","volume":"17","author":"Zhao","year":"2022","journal-title":"Mol Neurodegener"},{"key":"10.1016\/j.tjpad.2025.100214_bib0072","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.3233\/ADR-240089","article-title":"An open-label, pilot study of daratumumab SC in mild to moderate Alzheimer's disease","volume":"8","author":"Gordon","year":"2024","journal-title":"J Alzheimers Dis Rep"},{"key":"10.1016\/j.tjpad.2025.100214_bib0073","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1196413","article-title":"Alzheimer's disease and neuroinflammation: will new drugs in clinical trials pave the way to a multi-target therapy?","volume":"14","author":"Melchiorri","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.tjpad.2025.100214_bib0074","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14061240","article-title":"Treatment of neuronopathic mucopolysaccharidoses with blood-brain barrier-crossing enzymes: clinical application of receptor-mediated transcytosis","volume":"14","author":"Sonoda","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.tjpad.2025.100214_bib0075","doi-asserted-by":"crossref","first-page":"7067","DOI":"10.7150\/thno.73509","article-title":"Advancing (89)Zr-immuno-PET in neuroscience with a bispecific anti-amyloid-beta monoclonal antibody - the choice of chelator is essential","volume":"12","author":"Wuensche","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.tjpad.2025.100214_bib0076","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s40035-022-00324-y","article-title":"ImmunoPET imaging of amyloid-beta in a rat model of Alzheimer's disease with a bispecific, brain-penetrating fusion protein","volume":"11","author":"Bonvicini","year":"2022","journal-title":"Transl Neurodegener"},{"key":"10.1016\/j.tjpad.2025.100214_bib0077","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.neuroimage.2018.10.011","article-title":"High detection sensitivity with antibody-based PET radioligand for amyloid beta in brain","volume":"184","author":"Fang","year":"2019","journal-title":"Neuroimage"},{"key":"10.1016\/j.tjpad.2025.100214_bib0078","doi-asserted-by":"crossref","first-page":"302","DOI":"10.2967\/jnumed.121.262083","article-title":"(11)C-PiB and (124)I-antibody PET provide differing estimates of brain amyloid-beta after therapeutic intervention","volume":"63","author":"Meier","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.tjpad.2025.100214_bib0079","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.2967\/jnumed.118.213140","article-title":"Antibody-based in vivo PET imaging detects amyloid-beta reduction in alzheimer transgenic mice after BACE-1 inhibition","volume":"59","author":"Meier","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.tjpad.2025.100214_bib0080","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10759","article-title":"Antibody-based PET imaging of amyloid beta in mouse models of Alzheimer's disease","volume":"7","author":"Sehlin","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.tjpad.2025.100214_bib0081","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-17358-2","article-title":"Pharmacokinetics, biodistribution and brain retention of a bispecific antibody-based PET radioligand for imaging of amyloid-beta","volume":"7","author":"Sehlin","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.tjpad.2025.100214_bib0082","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1007\/s00259-019-04426-0","article-title":"Engineered antibodies: new possibilities for brain PET?","volume":"46","author":"Sehlin","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.tjpad.2025.100214_bib0083","doi-asserted-by":"crossref","first-page":"4460","DOI":"10.1021\/acschemneuro.0c00652","article-title":"Fluorine-18-labeled antibody ligands for PET imaging of amyloid-beta in brain","volume":"11","author":"Syvanen","year":"2020","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.tjpad.2025.100214_bib0084","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.neuroimage.2017.01.004","article-title":"A bispecific tribody PET radioligand for visualization of amyloid-beta protofibrils - a new concept for neuroimaging","volume":"148","author":"Syvanen","year":"2017","journal-title":"Neuroimage"},{"key":"10.1016\/j.tjpad.2025.100214_bib0085","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1111\/jnc.16127","article-title":"Antibody engagement with amyloid-beta does not inhibit [(11)C]PiB binding for PET imaging","volume":"168","author":"Xiong","year":"2024","journal-title":"J Neurochem"},{"key":"10.1016\/j.tjpad.2025.100214_bib0086","doi-asserted-by":"crossref","first-page":"6319","DOI":"10.7150\/thno.97149","article-title":"PET imaging of microglia in Alzheimer's disease using copper-64 labeled TREM2 antibodies","volume":"14","author":"Shojaei","year":"2024","journal-title":"Theranostics"},{"key":"10.1016\/j.tjpad.2025.100214_bib0087","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.108985","article-title":"In vivo imaging of alpha-synuclein with antibody-based PET","volume":"208","author":"Roshanbin","year":"2022","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.tjpad.2025.100214_bib0088","doi-asserted-by":"crossref","first-page":"12806","DOI":"10.1073\/pnas.1509667112","article-title":"Noninvasive brain cancer imaging with a bispecific antibody fragment, generated via click chemistry","volume":"112","author":"Luo","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.tjpad.2025.100214_bib0089","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1158\/1078-0432.CCR-20-3243","article-title":"Imaging tumor-infiltrating lymphocytes in brain tumors with [(64)Cu]Cu-NOTA-anti-CD8 PET","volume":"27","author":"Nagle","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.tjpad.2025.100214_bib0090","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1021\/acsptsci.4c00037","article-title":"Development and preclinical evaluation of a copper-64-labeled antibody targeting glycine-alanine dipeptides for PET imaging of C9orf72-associated amyotrophic lateral sclerosis\/frontotemporal dementia","volume":"7","author":"Shojaei","year":"2024","journal-title":"ACS Pharmacol Transl Sci"},{"key":"10.1016\/j.tjpad.2025.100214_bib0091","doi-asserted-by":"crossref","DOI":"10.48101\/ujms.v129.10585","article-title":"Indium-111 radiolabelling of a brain-penetrant Abeta antibody for SPECT imaging","volume":"129","author":"Gustavsson","year":"2024","journal-title":"Ups J Med Sci"},{"key":"10.1016\/j.tjpad.2025.100214_bib0092","first-page":"15","article-title":"Pretargeted imaging beyond the blood-brain barrier-utopia or feasible?","author":"Lopes van den Broek","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.tjpad.2025.100214_bib0093","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40478-024-01734-x","article-title":"Altered amyloid-beta structure markedly reduces gliosis in the brain of mice harboring the Uppsala APP deletion","volume":"12","author":"Vega","year":"2024","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.tjpad.2025.100214_bib0094","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1038\/s41467-023-37632-4","article-title":"Targeting neuronal lysosomal dysfunction caused by beta-glucocerebrosidase deficiency with an enzyme-based brain shuttle construct","volume":"14","author":"Gehrlein","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.tjpad.2025.100214_bib0095","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aay1163","article-title":"Brain delivery and activity of a lysosomal enzyme using a blood-brain barrier transport vehicle in mice","volume":"12","author":"Ullman","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.tjpad.2025.100214_bib0096","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0229850","article-title":"Brain Shuttle Neprilysin reduces central Amyloid-beta levels","volume":"15","author":"Campos","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.tjpad.2025.100214_bib0097","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s13195-022-01132-2","article-title":"Blood-brain barrier penetrating neprilysin degrades monomeric amyloid-beta in a mouse model of Alzheimer's disease","volume":"14","author":"Rofo","year":"2022","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.tjpad.2025.100214_bib0098","doi-asserted-by":"crossref","first-page":"789","DOI":"10.7150\/thno.50263","article-title":"Enhanced neprilysin-mediated degradation of hippocampal Abeta42 with a somatostatin peptide that enters the brain","volume":"11","author":"Rofo","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.tjpad.2025.100214_bib0099","doi-asserted-by":"crossref","first-page":"eadi2245","DOI":"10.1126\/scitranslmed.adi2245","article-title":"Targeting the transferrin receptor to transport antisense oligonucleotides across the mammalian blood-brain barrier","volume":"16","author":"Barker","year":"2024","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.tjpad.2025.100214_bib0100","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.154142","article-title":"Antibody-oligonucleotide conjugate achieves CNS delivery in animal models for spinal muscular atrophy","volume":"7","author":"Hammond","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.tjpad.2025.100214_bib0101","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1126\/science.adm8386","article-title":"An AAV capsid reprogrammed to bind human transferrin receptor mediates brain-wide gene delivery","volume":"384","author":"Huang","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.tjpad.2025.100214_bib0102","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.neuron.2015.11.024","article-title":"Discovery of novel blood-brain barrier targets to enhance brain uptake of therapeutic antibodies","volume":"89","author":"Zuchero","year":"2016","journal-title":"Neuron"},{"key":"10.1016\/j.tjpad.2025.100214_bib0103","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.chembiol.2023.09.008","article-title":"Bispecific antibody shuttles targeting CD98hc mediate efficient and long-lived brain delivery of IgGs","volume":"31","author":"Pornnoppadol","year":"2024","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.tjpad.2025.100214_bib0104","doi-asserted-by":"crossref","DOI":"10.1021\/acschemneuro.4c00552","article-title":"Comparative Radiotracing Quantifies Brain Cellular Uptake and Catabolism of Bispecific Antibodies Targeting Transferrin Receptor and CD98hc","author":"Veire","year":"2025","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.tjpad.2025.100214_bib0105","doi-asserted-by":"crossref","first-page":"5053","DOI":"10.1038\/s41467-023-40681-4","article-title":"CD98hc is a target for brain delivery of biotherapeutics","volume":"14","author":"Chew","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.tjpad.2025.100214_bib0106","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12987-025-00624-1","article-title":"Increasing brain half-life of antibodies by additional binding to myelin oligodendrocyte glycoprotein, a CNS specific protein","volume":"22","author":"Cuypers","year":"2025","journal-title":"Fluids Barriers CNS"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S227458072500158X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S227458072500158X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T07:39:39Z","timestamp":1762673979000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S227458072500158X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":106,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S227458072500158X"],"URL":"https:\/\/doi.org\/10.1016\/j.tjpad.2025.100214","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bispecific brain-penetrant antibodies for treatment of Alzheimer\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tjpad.2025.100214","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Masson SAS on behalf of SERDI Publisher.","name":"copyright","label":"Copyright"}],"article-number":"100214"}}